Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, Alpha Diallo, Lambert Assoumou et al.|Critical Care|2023Cited by 47